Cohance Lifesciences Limited announced its unaudited standalone and consolidated financial results for the Quarter and Half year ended 30 September 2026. The Board of Directors also approved the appointment of Dr. Kuber Jagdale as an Additional Director and Chief Technical Officer & Executive Director for a period of five years, effective 7 November 2026. Additionally, the Board approved a proposed equity investment of 26% in a Special Purpose Vehicle (SPV) for solar power generation.
Board Approves Q2 FY27 Financials and Strategic Appointments
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced the outcome of its Board of Directors’ meeting held on 6 November 2026. The Board has approved the unaudited standalone and consolidated financial results for the Quarter and Half year ended 30 September 2026, as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Financial Highlights
The financial results indicate a revenue of ₹4,766 million for Q2 FY27, a decrease of 14.2% year-on-year, but a sequential growth of 12.9%. Adjusted EBITDA for Q2 FY27 stood at ₹459 million, with margins at 10%. The first half of FY27 saw revenues of ₹8,989 million, down 18.6% year-on-year, with Adjusted EBITDA at ₹551 million and a margin of 6.1%.
Appointment of Additional Director
In a significant governance move, the Board has approved the appointment of Dr. Kuber Jagdale (DIN: 12037580) as an Additional Director. He will also serve as the Chief Technical Officer & Executive Director for a period of five years, commencing from 7 November 2026 and concluding on 6 November 2031. This appointment is subject to shareholder and other applicable approvals. Dr. Jagdale brings over three decades of experience in the pharmaceutical industry, with leadership roles at major companies like Cipla Limited, Sekhmet Pharma Ventures, and Emcure Pharmaceuticals Limited. His expertise spans manufacturing operations, API and FDF production, quality management, and supply chain management. Importantly, Dr. Jagdale is not related to any existing directors or Key Managerial Personnel, and is not debarred from holding a directorial position.
Strategic Investment in Solar Power
The company also approved a proposed equity investment of 26% in a Special Purpose Vehicle (SPV) that is currently under incorporation. This SPV will be engaged in solar power generation, with a contracted capacity of 5.3 MW Wind and 4.45 MWp Solar, intended for captive power consumption for Cohance’s plant operations. The acquisition is expected to help achieve Green Industry status, reduce CO2 emissions, and provide tariff savings of approximately 26% while ensuring green energy consumption and operational expenditure savings.
Further Details
Detailed information regarding the appointment of Dr. Kuber Jagdale is provided in Annexure-II, and details concerning the acquisition are in Annexure-III. The company has also made this information available on its website, www.cohance.com.
Source: BSE
